IPIX has issued 7 PR’s and 2 additional Sharehol
Post# of 72440
(Total Views: 495)
Posted On: 03/10/2020 11:24:01 PM
IPIX has issued 7 PR’s and 2 additional Shareholder emails in the past 3 weeks focusing specifically on the possibility of Brilacidin as a treatment for the COVID-19 virus. IMO each of these 9 communications has gotten progressively more detailed and confident. The first of these 9 was on 2/18/20 entitled “Defensins conceptually ideal for viral infections”. After that PR I felt Brilacidin was a longshot for COVID-19 treatment and that it would simply be icing on the cake of an already robust portfolio of B for B-OM and B-IBD Oral. Today’s PR noted that a Regional Biocontainment Lab has B in hand and is scheduled to test B next week. Today’s PR also has a very convincing scientific argument for B as a safety tested, efficacy tested and much needed treatment as noted below. I no longer believe Brilacidin is a longshot for COVID-19 treatment. I now believe we have a whole new market that could save millions of lives and if someone needs to make some money saving these lives, it might as well be us.
===================================
There are currently no countermeasures approved by the U.S. Food and Drug Administration for treating COVID-19. On Friday, March 6, President Donald Trump signed an emergency bill allocating $8.3 billion in funds to combat COVID-19.
Brilacidin is a compelling investigational drug for COVID-19 due to its unique qualities to mimic the human innate immune system and Mechanism of Action that includes disruption of the membrane of pathogens, leading to cell death. Throughout laboratory and clinical studies, Brilacidin has demonstrated potent activity against Gram-positive bacteria, including Methicillin-resistant Staphylococcus aureus (MRSA), and coverage against Gram-negative bacteria. Research supports the ability of Brilacidin to swiftly penetrate a peptidoglycan layer in these difficult bacteria, which is key to rapid pathogen destruction and decreases the likelihood of drug resistance emerging.
The ability to penetrate cell walls engenders confidence in this opportunity to meet an urgent medical need in treating coronaviruses like COVID-19. COVID-19 is an “enveloped” virus, meaning it has a glycoprotein envelope surrounding its nucleocapsid. More succinctly, it has a lipid envelope derived from the host cell membranes studded with crown-like projections from which it is named.
The Company hopes to disclose the RBL’s research agenda for Brilacidin in the coming days. The upcoming research is being funded by third parties independent of Innovation Pharmaceuticals. The Company’s responsibility was only providing the Brilacidin and any requested data. The RBL now has the Brilacidin on site, as disclosed on Monday, March 9, 2020.
Penetrating the COVID-19 envelope could prove beneficial in designing a new drug or vaccine against the virus, although this would have to be confirmed through extensive laboratory and clinical research. No assurances are made or implied that testing will be successfully completed by the RBL or any other party.
As previously released, linked below (a downloadable pdf) is an overview document summarizing the scientific rationale for developing Brilacidin as a potential novel COVID-19 treatment, both as an intravenous medicine and as a vaccine.
===================================
There are currently no countermeasures approved by the U.S. Food and Drug Administration for treating COVID-19. On Friday, March 6, President Donald Trump signed an emergency bill allocating $8.3 billion in funds to combat COVID-19.
Brilacidin is a compelling investigational drug for COVID-19 due to its unique qualities to mimic the human innate immune system and Mechanism of Action that includes disruption of the membrane of pathogens, leading to cell death. Throughout laboratory and clinical studies, Brilacidin has demonstrated potent activity against Gram-positive bacteria, including Methicillin-resistant Staphylococcus aureus (MRSA), and coverage against Gram-negative bacteria. Research supports the ability of Brilacidin to swiftly penetrate a peptidoglycan layer in these difficult bacteria, which is key to rapid pathogen destruction and decreases the likelihood of drug resistance emerging.
The ability to penetrate cell walls engenders confidence in this opportunity to meet an urgent medical need in treating coronaviruses like COVID-19. COVID-19 is an “enveloped” virus, meaning it has a glycoprotein envelope surrounding its nucleocapsid. More succinctly, it has a lipid envelope derived from the host cell membranes studded with crown-like projections from which it is named.
The Company hopes to disclose the RBL’s research agenda for Brilacidin in the coming days. The upcoming research is being funded by third parties independent of Innovation Pharmaceuticals. The Company’s responsibility was only providing the Brilacidin and any requested data. The RBL now has the Brilacidin on site, as disclosed on Monday, March 9, 2020.
Penetrating the COVID-19 envelope could prove beneficial in designing a new drug or vaccine against the virus, although this would have to be confirmed through extensive laboratory and clinical research. No assurances are made or implied that testing will be successfully completed by the RBL or any other party.
As previously released, linked below (a downloadable pdf) is an overview document summarizing the scientific rationale for developing Brilacidin as a potential novel COVID-19 treatment, both as an intravenous medicine and as a vaccine.
(16)
(0)Innovation Pharmaceuticals Inc (IPIX) Stock Research Links
Scroll down for more posts ▼